Sofosbuvir - a new drug for Hepatitis C treatment 
 
Sofosbuvir (Hepcinat, Sovaldi) - pills for oral consumption, used in hepatitis C treatment. The drug works by inhibiting RNA polymerase, which is used by the virus to replicate its RNA polymerase. Sofosbuvir was developed by Gilead Sciences, Inc pharmaceutical company. In December 2013  Sofosbuvir was approved by the FDA (Food and Drug Administration) as part of combination therapy in hepatitis C treatment. 
Sofosbuvir is indicated for patients with hepatitis C treatment and in patients simultaneously infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV): 
• Hepatitis Genotype 1 or 4: sofosbuvir plus peginterferon-alfa and Ribavirin for 12 weeks 
• Genotype 2: Sofosbuvir and Ribavirin within 12 weeks and more 
• Genotype 3: Sofosbuvir and Ribavirin within 24 weeks and more 
• In the case of hepatocellular carcinoma and liver transplantation: Sofosbuvir and Ribavirin for 48 weeks or until transplantation. This is necessary in order to avoid re-infection after organ transplantation. 
 
The drug was studied among a wide range of population, including people 65 years and older and those with mild and moderate renal insufficiency. Also, Sofosbuvir (Hepcinat) will be effective in patients with compensated cirrhosis. Sofosbuvir should not be taken during pregnancy and no studies have been made on the influence of the drug on children up to 18 years. 
 
DOSAGE 
Sofosbuvir (Hepcinat) is sold in pill form of 400 mg, the drug is taken orally once a day, regardless of the food consumption. 
 
SIDE EFFECTS 
Sofosbuvir was very well tolerated during clinical trials. The most common side effects are observed while Sofosbuvir (Hepcinat) admission in conjunction with ribavirin, basically it is fatigue and headache. 
Interactions with other drugs 
The joint use of Sofosbuvir (Hepcinat) with the following drugs is not recommended because they can greatly reduce its intestinal absorption: 
Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital and phenytoin 
Antimycobacterial drugs: rifabutin, rifampin, rifapentine 
Herbal supplements: tutsan 
HIV protease inhibitors: tipranavir, ritonavir 
CLINICAL STUDIES 
Studies have shown that Sofosbuvir (Hepcinat) in combination with other drugs can achieve sustained virological response in 92% of cases. 
<a href="https://bitcointalk.org/index.php?topic=1174203.0#ar1x" rel="nofollow">Sovaldi Sofosbuvir</a>